Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts.
Todeschini P, Salviato E, Paracchini L, Ferracin M, Petrillo M, Zanotti L, Tognon G, Gambino A, Calura E, Caratti G, Martini P, Beltrame L, Maragoni L, Gallo D, Odicino FE, Sartori E, Scambia G, Negrini M, Ravaggi A, D'Incalci M, Marchini S, Bignotti E, Romualdi C. Todeschini P, et al. Cancer Lett. 2017 Mar 1;388:320-327. doi: 10.1016/j.canlet.2016.12.017. Epub 2016 Dec 22. Cancer Lett. 2017. PMID: 28017893
FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA, Todeschini P, Siegel ER, Calza S, Cappella P, Ardighieri L, Cadei M, Bugatti M, Romani C, Bandiera E, Zanotti L, Tassone L, Guarino D, Santonocito C, Capoluongo ED, Beltrame L, Erba E, Marchini S, D'Incalci M, Donzelli C, Santin AD, Pecorelli S, Sartori E, Bignotti E, Odicino F, Ravaggi A. Tassi RA, et al. Among authors: todeschini p. J Exp Clin Cancer Res. 2017 May 8;36(1):63. doi: 10.1186/s13046-017-0536-y. J Exp Clin Cancer Res. 2017. PMID: 28482906 Free PMC article.
MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis.
Zanotti L, Romani C, Tassone L, Todeschini P, Tassi RA, Bandiera E, Damia G, Ricci F, Ardighieri L, Calza S, Marchini S, Beltrame L, Tognon G, D'Incalci M, Pecorelli S, Sartori E, Odicino F, Ravaggi A, Bignotti E. Zanotti L, et al. Among authors: todeschini p. BMC Cancer. 2017 May 25;17(1):366. doi: 10.1186/s12885-017-3334-1. BMC Cancer. 2017. PMID: 28545541 Free PMC article.
FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients.
Tassi RA, Gambino A, Ardighieri L, Bignotti E, Todeschini P, Romani C, Zanotti L, Bugatti M, Borella F, Katsaros D, Tognon G, Sartori E, Odicino F, Romualdi C, Ravaggi A. Tassi RA, et al. Among authors: todeschini p. Br J Cancer. 2019 Oct;121(7):584-592. doi: 10.1038/s41416-019-0553-z. Epub 2019 Aug 22. Br J Cancer. 2019. PMID: 31434988 Free PMC article.
Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer.
Benvenuto G, Todeschini P, Paracchini L, Calura E, Fruscio R, Romani C, Beltrame L, Martini P, Ravaggi A, Ceppi L, Sales G, Donati F, Perego P, Zanotti L, Ballabio S, Grassi T, Delle Marchette M, Tognon G, Sartori E, Adorni M, Odicino F, D'Incalci M, Bignotti E, Romualdi C, Marchini S. Benvenuto G, et al. Among authors: todeschini p. Int J Cancer. 2020 Jul 15;147(2):565-574. doi: 10.1002/ijc.32935. Epub 2020 Mar 13. Int J Cancer. 2020. PMID: 32096871 Free article.
Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients.
Bignotti E, Ragnoli M, Zanotti L, Calza S, Falchetti M, Lonardi S, Bergamelli S, Bandiera E, Tassi RA, Romani C, Todeschini P, Odicino FE, Facchetti F, Pecorelli S, Ravaggi A. Bignotti E, et al. Among authors: todeschini p. Br J Cancer. 2011 Apr 26;104(9):1418-25. doi: 10.1038/bjc.2011.109. Epub 2011 Apr 5. Br J Cancer. 2011. PMID: 21468050 Free PMC article.
Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence.
Tassi RA, Calza S, Ravaggi A, Bignotti E, Odicino FE, Tognon G, Donzelli C, Falchetti M, Rossi E, Todeschini P, Romani C, Bandiera E, Zanotti L, Pecorelli S, Santin AD. Tassi RA, et al. Among authors: todeschini p. BMC Cancer. 2009 Jul 27;9:253. doi: 10.1186/1471-2407-9-253. BMC Cancer. 2009. PMID: 19635143 Free PMC article.
93 results